Scilex Holding Co's total inventories for the quarter that ended in Jun. 2024 was $3.07 Mil. Scilex Holding Co's average total inventories from the quarter that ended in Mar. 2024 to the quarter that ended in Jun. 2024 was $3.28 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Scilex Holding Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was $-2.33.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Scilex Holding Co's Days Inventory for the
three
months ended in Jun. 2024 was 68.17.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Scilex Holding Co's Inventory Turnover for the quarter that ended in Jun. 2024 was 1.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Scilex Holding Co's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.20.
Scilex Holding Co Total Inventories Historical Data
The historical data trend for Scilex Holding Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Scilex Holding Co (NAS:SCLX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Scilex Holding Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Scilex Holding Co's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Scilex Holding Co Total Inventories Related Terms
Thank you for viewing the detailed overview of Scilex Holding Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCLX has been successfully added to your 